sglt2 inhibitors vs glp 1 agonists View of Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, and long-acting GLP-1 receptor complement each other to save lives by different mechanisms? SGLT2 Inhibitors vs. GLP-1 Agonists
Description
The promise of new and advanced GLP-1 therapies is encouraging with new products speculated to enter the market as soon as mid 2023

Nguyen said both the enrollment and prescription growth greatly exceeded their initial goal of a 10% increase in prescriptions in 2024

Rybelsus (semaglutide): An oral formulation of semaglutide manufactured by Novo Nordisk, Rybelsus has been named in MDL 3094

R01DK133465)

PMCID: PMC10154650
